Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: CuttingEdge Bio who wrote (3268)	3/24/2021 8:33:17 PM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 3557

If [REGN] can show the PK is sufficiently similar and the viral-load impact is the same, there is no reason to believe the SubQ will be behaving any differently for the question of outcomes! I agree with the above if you’re talking about what’s sufficient for an EUA. However, to garner meaningful commercial uptake (i.e. to move the needle for REGN), I think the subQ formulation will need some actual outcomes data. Not on the same scale as the IV dataset, of course.